Alkermes PLC Stock Upgraded (ALKS)

NEW YORK ( TheStreet) -- Alkermes (Nasdaq: ALKS) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the ratings report include:
  • ALKS's very impressive revenue growth greatly exceeded the industry average of 8.1%. Since the same quarter one year prior, revenues leaped by 146.0%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The current debt-to-equity ratio, 0.50, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 4.21, which clearly demonstrates the ability to cover short-term cash needs.
  • Compared to where it was a year ago today, the stock is now trading at a higher level, reflecting both the market's overall trend during that period and the fact that the company's earnings growth has been robust. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 269.4% when compared to the same quarter one year prior, rising from -$13.24 million to $22.43 million.
  • Net operating cash flow has significantly increased by 74.26% to -$4.70 million when compared to the same quarter last year. In addition, ALKERMES PLC has also vastly surpassed the industry average cash flow growth rate of -75.38%.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. Alkermes has a market cap of $2.55 billion and is part of the health care sector and drugs industry. Shares are up 30.8% year to date as of the close of trading on Tuesday.

You can view the full Alkermes Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round